SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2010 / Cilt: 20 - Sayı: 3

Significance of hormonal treatment in metastatic breast cancer

Metastatik meme kanserinde hormonal tedavinin önemi

UMUT DEMİRCİ
Süleyman BÜYÜKBERBER
Ramazan YILDIZ
Mustafa BENEKLİ
Uğur COŞGUN
Pages
186–189
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We give consecutive chemotherapy and hormonal treatment and show that metastatic lesions disappeared after hormonal treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In recent years mortality of breast cancer was decreased with frequent useage of mammography and effective adjuvant treatment regiments.
📊
Key Findings & Data:But unfortunately we can not see the same success in metastatic breast cancer.
💡
Conclusion & Impact:We give consecutive chemotherapy and hormonal treatment and show that metastatic lesions disappeared after hormonal treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In recent years mortality of breast cancer was decreased with frequent useage of mammography and effective adjuvant treatment regiments. But unfortunately we can not see the same success in metastatic breast cancer. Because we can not achive curative treatment in metastatic breast cancer; the aim of the treatment is sympthomatic improvement and increse in survival. In this case we emphasize the role of hormonal treatment in metastatic breast cancer. We give consecutive chemotherapy and hormonal treatment and show that metastatic lesions disappeared after hormonal treatment.

Özet

Son yıllarda meme kanserinde mammografinin yaygın kullanılması ve efektif adjuvan tedavi yöntemleri ile mortalitede önemli başarı sağlanmışken benzer oranda bir başarı metastatik hastalıkta elde edilememiştir. Metastatik meme kanserinde küratif tedavi şansı yoktur amaç semptomları hafifletmek ve sağkalımı uzatmaktır. Biz tanıda metastatik hastalığı olan ardışık olarak kemoterapi ve hormonal tedavi uyguladığımız hormonal tedavi altında metastatik lezyonları kaybolan hastayı özellikle hor monal tedavinin önemini vurgulamak için sunduk.

🔖

Cite This Article

DEMİRCİ, U., BÜYÜKBERBER, S., YILDIZ, R., BENEKLİ, M., COŞGUN, U. (2010). Significance of hormonal treatment in metastatic breast cancer. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 20 - Sayı: 3, 186–189. https://ajindex.com/articles/323283

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ahmedin Jemal, Ram C. Tiwari, Taylor Murray, et al. Cancer Statistics. Cancer J Clin 54: 8-29, 2004
  2. Sunderland MC, Osborne CK. Tamoxifen in premena uposal patients with metastatic breast cancer: A revi ew. J Clin Oncol 9: 1283-1297, 1986
  3. Wittliff JL. Steroid hormone receptors in breast cancer. Cancer 53: 630, 1984
  4. Falkson G, Holcroft C, Gelman RS, et al. Ten-year fol low up study of premenopausal women with metasta tic breast carcinoma: an eastern cooperative oncology group study. J Clin Oncol 13: 1453-1458, 1995
  5. Rahman ZU, Frye DK, Smith TL, et al. Results and long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxoru bicin-containing chemotherapy: a reference. Cancer 85: 104-111, 1999
  6. Hortobagyi GH. Treatment of breast cancer. N Engl J Med 339: 974-984, 1998
  7. Gennari A, Conte P, Rosso R, et al. Survival of metas tatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104: 1742- 1750, 2005
  8. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. A ran domized trial in postmenopausal patients with advan ced breast cancer comparing endocrine and cytotox ic therapy given sequentially or in combination. J Clin Oncol 4: 186-193, 1986. 9. http://mrw.interscience.wiley.com/cochrane/clsys rev/articles/CD002747/frame.html
  9. Muss HB. Breast cancer and differential diagnosis of benign lesions. In: Cecil Medicine. Goldman L, Ausiel lo D (eds). 23rd ed. Philadelphia, Saunders Elsevier, 2007: 1501-1510
  10. Kantarjian HM, Wolff RA, Koller CA. Metastatic Breast Cancer. In: MD Anderson Manual of Medical Oncolo gy. Kantarjian HM, Wolff RA, Koller CA (eds). McGraw- Hill 2007: Chapter 20
  11. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with ad vanced breast cancer: phase III trial results. J Clin On col 20: 2812-2823, 2002.